Dr. Jennifer Chheda has more than 25 years of experience in procuring and enforcing patents relating to biologics and small molecules, such as gene therapy, RNA (ribonucleic acid) therapeutics, antibodies, antibody drug conjugates, cell-based therapies (CAR-T cells), vaccines, and enzyme replacement therapy. She has experience developing, implementing, and managing worldwide patent portfolios covering commercial biologics and pharmaceuticals as well as products in development, including clinical candidates. Jennifer has worked with pioneers developing vaccines, such as a universal influenza virus vaccine, and virus-based cancer vaccines.
Jennifer's experience also includes patentability, invalidity, noninfringement, freedom-to-operate, and inventorship analyses and conducting due diligence for potential investors, acquirers, and licensees, such as venture capital firms, biotechnology companies, and pharmaceutical companies.
Jennifer has experience coordinating worldwide litigations and invalidation proceedings to ensure consistency between the litigations and proceedings. She has provided strategic advice regarding invalidity and infringement contentions. Jennifer's experience prosecuting patent applications globally has proved to be beneficial in the development of arguments relevant to non-U.S. jurisdictions in global proceedings. She also has provided strategic advice to clients regarding Patent Trial and Appeal (PTAB) proceedings, such as inter partes review, interferences, and reexaminations, and other post-grant proceedings, such as oppositions. Her scientific background has proved to be an asset in working with experts to develop reports and to prepare them for depositions and trial. Jennifer has worked on trade secret and patent cases.
Jennifer also has experience drafting and negotiating intellectual property agreements, including license, sponsored research, and development agreements. She has provided IP advice in the context of M&A transactions and has advised clients such as AbbVie, REGENXBIO, and Celgene in IP-related transactions.
- April 9, 2016
PharmaDJ Roundtable Discussion on Biosimilar and Antibody Development: Options for Asian Biosimilar Companies in the U.S.
- October 28, 2010
The Advent of Biosimilars: What you (and your clients) should know
- New York Law School (J.D. 2002); New York University (Ph.D. in Microbiology 1999; M.Sc. in Microbiology 1994); University of Connecticut (B.S. in Molecular and Cellular Biology cum laude 1992)
- New York and registered to practice before the United States Patent and Trademark Office
Named among the "Top 50 Women Leaders in Law" of 2023 by Women We Admire